Obesity Drugs
5 articles on Obesity Drugs, written by Shotlee and medically reviewed for clinical accuracy.
Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market
While GLP-1R agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) dominate the obesity market, non-GLP-1R targets are poised for explosive growth. Sales for these alternatives are expected to surge almost 50-fold from $310m in 2026 to $15.5bn in 2031, driven by calcitonin receptor drugs. This diversification signals a reshaping of the $172.6bn obesity pharmaceutical landscape by 2031.
5 min read
Eli Lilly Grabs Biggest Slice of GLP-1 Gold Rush Over Ozempic
Eli Lilly has overtaken Novo Nordisk in the GLP-1 gold rush, with Mounjaro and Zepbound now holding 60% of the U.S. market versus Ozempic and Wegovy's 39%. Backed by blockbuster revenue growth and superior weight loss results in head-to-head studies, Lilly's tirzepatide drugs are reshaping obesity and diabetes treatment. Investors and patients alike are taking notice of this shift.
5 min read
FDA Expedited Drug Program Raises Safety Concerns for Obesity Meds
The FDA's Commissioner's National Priority Voucher program aims to approve drugs in as little as one month, including anti-obesity medications. Staff and experts raise alarms over skipped steps, legal risks, and safety issues, like patient deaths in trials. Traditional six-to-10-month reviews ensure rigorous safety checks for GLP-1 drugs.
4 min read
AbbVie: Amylin Alternative to GLP-1 for Obesity Treatments
AbbVie is bolstering its obesity portfolio with GUBamy, an amylin-based drug from Gubra as a GLP-1 alternative. Unlike gut hormone-mimicking GLP-1s like Wegovy and Zepbound, amylin targets pancreatic hormones for improved tolerability and muscle retention. The company eyes long-term efficacy amid a $150B market boom.
1 min read
Health Minister Advances Wegovy's PBS Inclusion
The Australian government is set to partner with manufacturers to make Wegovy available on the Pharmaceutical Benefits Scheme for obesity management. This follows expert recommendations from the PBAC, addressing high private costs and equity in healthcare access.
2 min read